Movement disorders in neuropsychiatry

Current Opinion in Psychiatry

Volumn 9, Issue 1, 1996, Pages 85-88

  Lohr, James B ^a,b   Browning, John A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

AKATHISIA; BRADYKINESIA; COMPREHENSION; CORPUS CALLOSUM; DEPRESSION; DYSKINESIA; DYSTONIA; HUMAN; HUNTINGTON CHOREA; HYPERACTIVITY; MOTOR DYSFUNCTION; NEUROPSYCHIATRY; PARKINSON DISEASE; PSYCHIATRY; READING; SCHIZOPHRENIA; SHORT SURVEY; TARDIVE DYSKINESIA;

EID: 0030067038     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-199601000-00017     Document Type: Short Survey

References (20)

1. Aguilar EJ, Keshavan MS, Martinez-Quiles MD, Hernández J, Gómez-Beneyto M, Schooler NR: Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994, 151:1819-1821.
2. Sachdev P, Kruk J: Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994, 51:963-974. This is one of the largest studies examining the acute incidence of akathisia in a recently admitted inpatient population. In the first 2 weeks, 41% of 100 consecutively admitted patients developed mild akathisia, and an additional 21% developed akathisia in the moderate to severe range.
3. Halstead SM, Barnes TRE, Speller JC: Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br J Psychiatry 1994, 164:177-183. In this study, 120 chronic inpatients were examined for the prevalence of different subtypes of akathisia. Chronic akathisia was diagnosed in 24%, and pseudoakathisia, in which there is no subjective complaint of restlessness, was diagnosed in 18%. Younger patients seemed at greater risk for akathisia and men were at greater risk for pseudoakathisia.
4. Silver H, Geraisy N, Schwatz M: No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995, 56:167-170.
5. Fenton WS, Wyatt RJ, McGlashan TH: Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 1994, 51:643-650. The authors performed a retrospective record survey on 100 patients in the Chestnut Lodge follow-up study of patients who had never been treated with neuroleptic medication. They found evidence of a movement disorder in 23%, with 15% have clear-cut documentation of orofacial dyskinesias. These numbers are higher than most previous reports of spontaneous dyskinesias, which have generally been in the range of 5-10%.
6. Sweet RA, Mulsant BH, Gupta B, Rifai AH, Pasternak RE, McEachran A, Zubenko GS: Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch Gen Psychiatry 1995, 52:478-486. This is a large-scale study of risk factors for tardive dyskinesia in a group of patients aged 60-100 years, with a mean age of 75 years. Whereas only 16% of patients with a duration of neuroleptic treatment of less than 3 months had tardive dyskinesia, this increased to 29% for 3-12 months, 30% for 1-10 years, and 41% for greater than 10 years.
7. Duke PJ, Pantelis C, Barnes TRE: South Westminster schizophrenia survey: alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry 1994, 164:630-636.
8. Rapaport MH, Lohr JB. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand 1994, 90:311-315.
9. Hegerl U, Juckel G, Müller-Schubert A, Pietzcker A, Gaebel W: Schizophrenics with small P300: a subgroup with a neurodevelopmental disturbance and a high risk for tardive dyskinesia? Acta Psychiatr Scand 1995, 91:120-125.
10. Sewell DD, Kodsi AB, Caligiuri MP, Jesle DV: Metoclopramide and tardive dyskinesia. Biol Psychiatry 1994, 36:630-632. This is an interesting report which points out that tardive dyskinesia may occur in a nonpsychiatric setting, specifically as a result of the antiemetic neuroleptic drug metaclopramide, which is frequently used for diabetic gastroparesis and for nausea resulting from chemotherapy.
11. Lohr JB, Browning JA: Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull 1995, 31:159-165. The authors provide a brief review of the possible involvement of free radicals in different neuropsychiatric illnesses, including tardive dyskinesia and schizophrenia.
12. Meltzer HY: An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994, 55(suppl B):47-52. This is an excellent overview of the pharmacology of clozapine, including the potential importance of the dopamine D4 receptor and serotonin blockade for the atypical properties of the drug.
13. Davé M: Clozapine-related tardive dyskinesia. Biol Psychiatry 1994, 35:886-887.
14. Gerlach J, Peacock L: Motor and mental side effects of clozapine. J Clin Psychiatry 1994, 55(suppl B):107-109.
15. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM: Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994, 55(suppl B): 102-106.
16. Thomas P, Lalaux N, Baiba G, Goudemand M: Dose-dependent stuttering and dystonia in a patient taking clozapine. Am J Psychiatry 1994, 151:1096.
17. Worrall R, Wilson A, Cullen M: Dystonia and drug-induced hepatitis in a patient treated with clozapine. Am J Psychiatry 1995, 152:647-648.
18. Gupta S, Black DW, Smith DA: Risperidone: review of its pharmacology and therapeutic use in schizophrenia. Ann Clin Psychiatry 1994, 6: 173-180.
19. Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RSJ, Dolan RJ: Depression in Parkinson's disease: a positron emission study. Br J Psychiatry 1994, 165:333-339. The investigators performed a positron emission tomography study of regional cerebral blood flow in 10 patients with Parkinson's disease and major depression and compared the findings with those of 10 patients with Parkinson's disease without depression, 10 patients with primary depression and 10 control individuals. In both the depressed Parkinson's disease group, bilateral decreases in blood flow were observed in the medial prefrontal cortex and cingulate cortex. Similar findings were seen in the medial prefrontal cortex of the primary depression group, but not of the other groups. These findings indicate that the medial prefrontal cortex may be involved in depression.
20. Shiwach RS, Norbury CG: A controlled psychiatric study of individuals at risk for Huntington's disease. Br J Psychiatry 1994, 165:500-505.